Entera Bio annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Entera Bio Free Cash Flow (FCF) History (ENTX)
Entera Bio reported −$7.5M in free cash flow for fiscal 2025, a decrease of $656,000 from the previous fiscal year, with a free cash flow margin of −17802.38%.
View full Entera Bio company overviewEntera Bio free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$7.5M | −$656,000 | — | −17802.38% |
| 2024 | 2024-12-31 | −$6.8M | $506,000 | — | −3768.51% |
| 2023 | 2023-12-31 | −$7.3M | $5.2M | — | — |
| 2022 | 2022-12-31 | −$12.5M | −$3.5M | — | −9362.69% |
| 2021 | 2021-12-31 | −$9.1M | $1.5M | — | −1590.19% |
| 2020 | 2020-12-31 | −$10.6M | −$1.7M | — | −2906.85% |
| 2019 | 2019-12-31 | −$9.0M | $905,000 | — | −3796.19% |
| 2018 | 2018-12-31 | −$9.9M | −$5.3M | — | −1972.80% |
| 2017 | 2017-12-31 | −$4.6M | −$1.4M | — | — |
| 2016 | 2016-12-31 | −$3.2M | — | — | — |
Entera Bio quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.5M | −$1.8M | — | — |
| Q1 2026 | 2026-03-31 | −$3.1M | −$1.7M | — | — |
| Q4 2025 | 2025-12-31 | −$1.9M | −$390,000 | — | — |
| Q3 2025 | 2025-09-30 | −$2.5M | −$391,000 | — | — |
| Q2 2025 | 2025-06-30 | −$1.7M | −$325,000 | — | — |
| Q1 2025 | 2025-03-31 | −$1.4M | $450,000 | — | −3361.90% |
| Q4 2024 | 2024-12-31 | −$1.5M | $1.2M | — | −1792.68% |
| Q3 2024 | 2024-09-30 | −$2.2M | −$629,000 | — | −5128.57% |
| Q2 2024 | 2024-06-30 | −$1.3M | $225,000 | — | −2342.11% |
| Q1 2024 | 2024-03-31 | −$1.9M | −$242,000 | — | — |
| Q4 2023 | 2023-12-31 | −$2.6M | −$608,000 | — | — |
| Q3 2023 | 2023-09-30 | −$1.5M | $1.3M | — | — |
| Q2 2023 | 2023-06-30 | −$1.6M | $1.3M | — | — |
| Q1 2023 | 2023-03-31 | −$1.6M | $3.2M | — | — |
| Q4 2022 | 2022-12-31 | −$2.0M | $508,000 | — | −14385.71% |
| Q3 2022 | 2022-09-30 | −$2.9M | −$755,000 | — | −35887.50% |
| Q2 2022 | 2022-06-30 | −$2.8M | −$725,000 | — | −6468.18% |
| Q1 2022 | 2022-03-31 | −$4.8M | −$2.5M | — | −7080.88% |
| Q4 2021 | 2021-12-31 | −$2.5M | — | — | −1528.48% |
| Q3 2021 | 2021-09-30 | −$2.1M | — | — | −1511.43% |
| Q2 2021 | 2021-06-30 | −$2.1M | — | — | −1945.87% |
| Q1 2021 | 2021-03-31 | −$2.3M | — | — | −1478.34% |
Entera Bio free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$10.6M to −$7.5M, a net increase of $3.1M. Entera Bio's latest reported quarter, Q2 2026, generated −$3.5M in free cash flow, a decrease of $1.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Entera Bio filings at SEC.gov ↗